Impact of MRI-evaluated neoadjuvant chemotherapy response on change of surgical recommendation in breast cancer

Annals of Surgery

Volumn 249, Issue 3, 2009, Pages 448-454

  Chen, Jeon Hor ^a,b   Feig, Byron A ^a   Hsiang, David J B ^c   Butler, John A ^c   Mehta, Rita S ^c   Bahri, Shadfar ^a   Nalcioglu, Orhan ^a   Su, Min Ying ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; DIAGNOSTIC IMAGING; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMAGING SYSTEM; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MASTECTOMY; MEDICAL DECISION MAKING; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL MASTECTOMY; PREDICTION; PRIORITY JOURNAL; SURGEON; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR VOLUME; BREAST TUMOR; DECISION MAKING; MIDDLE AGED; PATHOLOGY; REMISSION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DECISION MAKING; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MASTECTOMY; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; REMISSION INDUCTION;

EID: 63449130952     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31819a6e01     Document Type: Article

References (43)

1. McCready D, Holloway C, Shelley W, et al. Surgical management of early stage invasive breast cancer: a practice guideline. Can J Surg. 2005;48:185-194.
2. Whelan T, Levine M, Willan A, et al. Effect of a decision aid on knowledge and treatment decision making for breast cancer surgery: a randomized trial. JAMA. 2004;292:435-441.
3. Benda RK, Mendenhall NP, Lind DS, et al. Breast-conserving therapy (BCT) for early-stage breast cancer. J Surg Oncol. 2004;85:14-27.
4. Fischer U, Kopka L, Grabbe E. Breast carcinoma: effect of preoperative contrast-enhanced MR imaging on the therapeutic approach. Radiology. 1999;213:881-888.
5. Mieog JS, van der Hage JA, van de Velde CJ. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg. 2007;94:1189-1200.
6. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26:778-785.
7. Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006;24:1940-1949.
8. Kaufmann M, von Minckwitz G, Bear HD, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol. 2007;18:1927-1934.
9. Gralow JR, Burstein HJ, Wood W, et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 2008;26:814-819.
10. Loibl S, von Minckwitz G, Raab G, et al. Surgical procedures after neoad-juvant chemotherapy in operable breast cancer: results of the GEPARDUO trial. Ann Surg Oncol. 2006;13:1434-1442.
11. Jeruss JS, Mittendorf EA, Tucker SL, et al. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol. 2008;26:246-252.
12. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25:4414-4422.
13. Chen AM, Meric-Bernstam F, Hunt KK, et al. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol. 2004;22:2303-2312.
14. Peintinger F, Symmans WF, Gonzalez-Angulo AM, et al. The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer. 2006;107:1248-1254.
15. Oh JL, Dryden MJ, Woodward WA, et al. Locoregional control of clinically diagnosed multifocal or multicentric breast cancer after neoadjuvant chemotherapy and locoregional therapy. J Clin Oncol. 2006;24:4971-4975.
16. Chen AM, Meric-Bernstam F, Hunt KK, et al. Breast conservation after neoadjuvant chemotherapy. Cancer. 2005;103:689-695.
17. Akazawa K, Tamaki Y, Taguchi T, et al. Preoperative evaluation of residual tumor extent by three-dimensional magnetic resonance imaging in breast cancer patients treated with neoadjuvant chemotherapy. Breast J. 2006;12: 130-137.
18. Segara D, Krop IE, Garber JE, et al. Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? J Surg Oncol. 2007;96:474-480.
19. Smitt MC, Heltzel M. Women's use of resources in decision-making for early-stage breast cancer: results of a community-based survey. Ann Surg Oncol. 1997;4:564-569.
20. Temple WJ, Russell ML, Parsons LL, et al. Conservation surgery for breast cancer as the preferred choice: a prospective analysis. J Clin Oncol. 2006; 24:3367-3373.
21. American College of Radiology. Breast imaging reporting and data system atlas (BI-RADS atlas). Reston, VA: American College of Radiology, 2003.
22. Chen JH, Feig B, Agrawal G, et al. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer. 2008;112:17-26.
23. Mazouni C, Peintinger F, Wan-Kau S, et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoad-juvant chemotherapy does not adversely affect patient outcome. J Clin Oncol. 2007;25:2650-2655.
24. Sadetzki S, Oberman B, Zipple D, et al. Breast conservation after neoadjuvant chemotherapy. Ann Surg Oncol. 2005;12(6):480-7.
25. Opatt D, Morrow M, Hawley S, et al. Conflicts in decision-making for breast cancer surgery. Ann Surg Oncol. 2007;14:2463-2469.
26. Hiotis K, Ye W, Sposto R, et al. Predictors of breast conservation therapy: size is not all that matters. Cancer. 2005;103:892-899.
27. Kraus PL. Body image, decision making, and breast cancer treatment. Cancer Nurs. 1999;22:421-427.
28. Caldon LJ, Walters SJ, Ratcliffe J, et al. What influences clinicians' operative preferences for women with breast cancer? An application of the discrete choice experiment. Eur J Cancer. 2007;43:1662-1669.
29. Schou I, Ekeberg O, Ruland CM, et al. Do women newly diagnosed with breast cancer and consulting surgeon assess decision-making equally? Breast. 2002;11:434-441.
30. Romanek KM, McCaul KD, Sandgren AK. Age differences in treatment decision making for breast cancer in a sample of healthy women: the effects of body image and risk framing. Oncol Nurs Forum. 2005;32:799-806.
31. Mastaglia B, Kristjanson LJ. Factors influencing women's decisions for choice of surgery for Stage I and Stage II breast cancer in Western Australia. J Adv Nurs. 2001;35:836-847.
32. Rouzier R, Mathieu MC, Sideris L, et al. Breast-conserving surgery after neoadjuvant anthracycline-based chemotherapy for large breast tumors. Cancer. 2004;101:918-925.
33. Beriwal S, Schwartz GF, Komarnicky L, et al. Breast-conserving therapy after neoadjuvant chemotherapy: long-term results. Breast J. 2006;12:159-164.
34. Garimella V, Qutob O, Fox JN, et al. Recurrence rates after DCE-MRI image guided planning for breast-conserving surgery following neoadjuvant chemotherapy for locally advanced breast cancer patients. Eur J Surg Oncol. 2007;33:157-161.
35. Beatty JD, Porter BA. Contrast-enhanced breast magnetic resonance imaging: the surgical perspective. Am J Surg. 2007;193:600-605.
36. Julius T, Kemp SE, Kneeshaw PJ, et al. MRI and conservative treatment of locally advanced breast cancer. Eur J Surg Oncol. 2005;31:1129-1134.
37. Partridge SC, Gibbs JE, Lu Y, et al. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am J Roentgenol. 2002;179:1193-1199.
38. Belli P, Costantini M, Malaspina C, et al. MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy. Clin Radiol. 2006;61:946-953.
39. Weatherall PT, Evans GF, Metzger GJ, et al. MRI vs. histologic measurement of breast cancer following chemotherapy: comparison with x-ray mammography and palpation. J Magn Reson Imaging. 2001;13:868-875.
40. Bodini M, Berruti A, Bottini A, et al. Magnetic resonance imaging in comparison to clinical palpation in assessing the response of breast cancer to epirubicin primary chemotherapy. Breast Cancer Res Treat. 2004;85:211-218.
41. Chagpar AB, Middleton LP, Sahin AA, et al. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg. 2006;243:257-264.
42. Waljee JF, Hawley S, Alderman AK, et al. Patient satisfaction with treatment of breast cancer: does surgeon specialization matter? J Clin Oncol. 2007;25: 3694-3698.
43. Nold RJ, Beamer RL, Helmer SD, et al. Factors influencing a woman's choice to undergo breast-conserving surgery versus modified radical mastectomy. Am J Surg. 2000;180:413-418.